BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15670251)

  • 21. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.
    Jansen AC; van Aalst-Cohen ES; Tanck MW; Trip MD; Lansberg PJ; Liem AH; van Lennep HW; Sijbrands EJ; Kastelein JJ
    J Intern Med; 2004 Dec; 256(6):482-90. PubMed ID: 15554949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
    Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
    HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-factor clustering and cardiovascular disease risk in hypertensive patients.
    Weycker D; Nichols GA; O'Keeffe-Rosetti M; Edelsberg J; Khan ZM; Kaura S; Oster G
    Am J Hypertens; 2007 Jun; 20(6):599-607. PubMed ID: 17531915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes.
    Gimeno-Orna JA; Molinero-Herguedas E; Sánchez-Vaño R; Lou-Arnal LM; Boned-Juliani B; Castro-Alonso FJ
    Diabetes Res Clin Pract; 2006 Oct; 74(1):103-9. PubMed ID: 16621114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets.
    Normén L; Yip B; Montaner J; Harris M; Frohlich J; Bondy G; Hogg RS
    HIV Med; 2007 Sep; 8(6):346-56. PubMed ID: 17661842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes.
    Guech-Ongey M; Brenner H; Twardella D; Hahmann H; Rothenbacher D
    Int J Cardiol; 2006 Jul; 111(1):98-103. PubMed ID: 16229909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
    van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
    HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events.
    Albert MA; Glynn RJ; Buring J; Ridker PM
    Circulation; 2006 Dec; 114(24):2619-26. PubMed ID: 17116764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients.
    Targher G; Bertolini L; Zenari L; Lippi G; Pichiri I; Zoppini G; Muggeo M; Arcaro G
    Diabet Med; 2008 Jan; 25(1):45-50. PubMed ID: 18199131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exercise and cardiovascular outcomes by hypertensive status: NHANES I epidemiological follow-up study, 1971-1992.
    Fang J; Wylie-Rosett J; Alderman MH
    Am J Hypertens; 2005 Jun; 18(6):751-8. PubMed ID: 15925731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.